

Special Issue

CAR-T Cell in Human Cancers: Combinations, Gene-Editing, Payload Delivery, Autonomous Control and Synthetic Biology

Message from the Guest Editors

Chimeric antigen receptor T (CAR-T) cell therapies are having an unprecedented impact on the treatment of multiple malignancies. However, the limits of CARs as single-agent effectors, especially in the context of solid tumor treatment, are also crystalizing. The future of engineered cell therapeutics for cancer and beyond includes reprogramming cells with precise therapeutic circuits via synthetic biology, combinational treatment with immune checkpoint blockade and other immune modulators, and strategies to overcome T cell dysfunction/exhaustion and tumor exclusion. This Special Issue will highlight the platforms and approaches that are improving and advancing CAR-T cell development and ushering in the next generation of cell-based immunotherapies.

Guest Editors

Dr. Avery D. Posey

Department of Systems Pharmacology and Translational Therapeutics and Parker Institute for Cancer Immunotherapy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA

Dr. Kole T. Roybal

Department of Microbiology and Immunology, Parker Institute for Cancer Immunotherapy, Chan Zuckerberg Biohub, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94143, USA

Deadline for manuscript submissions

closed (30 April 2020)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/30707

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)